Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
In this study, researchers want to find the highest dose of the investigational drug ORIC-944 that can be given safely in people with metastatic prostate cancer that continues to grow despite standard treatments. ORIC-944 works by blocking a group of proteins called PRC2, which promote prostate cancer growth. It is taken orally (by mouth).
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread).
Researchers want to find the best dose of JNJ-79635322 to use in people with multiple myeloma or AL amyloidosis. The people in this study have multiple myeloma or AL amyloidosis that keeps growing even after treatment. Multiple myeloma is a cancer of the bone marrow. AL amyloidosis happens when a protein called amyloid builds up in organs and prevents them from working properly.
Researchers are comparing standard bladder cancer treatment with TAR-210. The people in this study have bladder cancer that has not grown into the muscle wall. Their cancer has a mutation (change) in the FGFR gene.
In this study, researchers are assessing a new way to determine the best dosing of fludarabine. The people in this study are children and young adults getting CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). Their cancer has come back or keeps growing despite treatment. They will be getting a CAR T-cell therapy called tisagenlecleucel (Kymriah).
The purpose of this study is to see if the combination of fianlimab, cemiplimab, and ipilimumab works well against melanoma. The people in this study have melanoma that is inoperable (cannot be taken out with surgery) or metastatic (spread). In addition, their cancer keeps growing even after treatment that included immunotherapy.
Researchers want to find the best dose of AZD0305 to use in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. AZD0305 is given intravenously (by vein).
Researchers want to learn if AMG 193 in combination with standard treatment is safe for people with advanced pancreatic cancer. The people in this study have pancreatic ductal adenocarcinoma (PDAC) that has metastasized (spread). In addition, their cancers have a mutation (change) in the MTAP gene. This results in a lack of the MTAP protein, which may help cancer grow.
Researchers are comparing taletrectinib with a placebo (inactive drug) in people with non-small cell lung cancer (NSCLC). The people in this study have stage 1B-3A NSCLC that has a ROS1 gene fusion. They have had the tumor completely removed with surgery.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
